Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Wayne A. Marasco, M.D., Ph.D.

TitleProfessor of Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana Farber Cancer Institute
450 Brookline Ave.
Boston MA 02215
Phone617/632-2153
Fax617/632-3889

 Research 
 research resources
This researcher has shared information about their research resources
in the eagle-i Network. To update or add resource records, contact
eagle-i@hms.harvard.edu.

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Hall SR, Jiang Y, Leary E, Yavanian G, Eminli S, O'Neill DW, Marasco WA. Identification and Isolation of Small CD44-Negative Mesenchymal Stem/Progenitor Cells From Human Bone Marrow Using Elutriation and Polychromatic Flow Cytometry. Stem Cells Transl Med. 2013 Aug; 2(8):567-78.
    View in: PubMed
  2. Zhang J, Valianou M, Simmons H, Robinson MK, Lee HO, Mullins SR, Marasco WA, Adams GP, Weiner LM, Cheng JD. Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens. FASEB J. 2013 Feb; 27(2):581-9.
    View in: PubMed
  3. Han T, Abdel-Motal UM, Chang DK, Sui J, Muvaffak A, Campbell J, Zhu Q, Kupper TS, Marasco WA. Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma. PLoS One. 2012; 7(9):e44455.
    View in: PubMed
  4. Braun SE, Taube R, Zhu Q, Wong FE, Murakami A, Kamau E, Dwyer M, Qiu G, Daigle J, Carville A, Johnson RP, Marasco WA. In vivo selection of CD4(+) T cells transduced with a gamma-retroviral vector expressing a single-chain intrabody targeting HIV-1 tat. Hum Gene Ther. 2012 Sep; 23(9):917-31.
    View in: PubMed
  5. Vyas JM, Marasco WA. Fatal fulminant hepatic failure from adenovirus in allogeneic bone marrow transplant patients. Case Rep Infect Dis. 2012; 2012:463569.
    View in: PubMed
  6. Chang DK, Sui J, Geng S, Muvaffak A, Bai M, Fuhlbrigge RC, Lo A, Yammanuru A, Hubbard L, Sheehan J, Campbell JJ, Zhu Q, Kupper TS, Marasco WA. Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells. Mol Cancer Ther. 2012 Nov; 11(11):2451-61.
    View in: PubMed
  7. Hammond SP, Gagne LS, Stock SR, Marty FM, Gelman RS, Marasco WA, Poritz MA, Baden LR. Respiratory virus detection in immunocompromised patients with FilmArray respiratory panel compared to conventional methods. J Clin Microbiol. 2012 Oct; 50(10):3216-21.
    View in: PubMed
  8. Chang H, Biswas S, Tallarico AS, Sarkis PT, Geng S, Panditrao MM, Zhu Q, Marasco WA. Human B-cell ontogeny in humanized NOD/SCID ?c(null) mice generates a diverse yet auto/poly- and HIV-1-reactive antibody repertoire. Genes Immun. 2012 Jul; 13(5):399-410.
    View in: PubMed
  9. Biswas S, Chang H, Sarkis PT, Fikrig E, Zhu Q, Marasco WA. Humoral immune responses in humanized BLT mice immunized with West Nile virus and HIV-1 envelope proteins are largely mediated via human CD5+ B cells. Immunology. 2011 Dec; 134(4):419-33.
    View in: PubMed
  10. Abdel-Motal UM, Sarkis PT, Han T, Pudney J, Anderson DJ, Zhu Q, Marasco WA. Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro. PLoS One. 2011; 6(10):e26473.
    View in: PubMed
  11. Han T, Sui J, Bennett AS, Liddington RC, Donis RO, Zhu Q, Marasco WA. Fine epitope mapping of monoclonal antibodies against hemagglutinin of a highly pathogenic H5N1 influenza virus using yeast surface display. Biochem Biophys Res Commun. 2011 Jun 3; 409(2):253-9.
    View in: PubMed
  12. Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, Huang CY, Liddington RC, Beigel JH, Marasco WA. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis. 2011 Apr 15; 52(8):1003-9.
    View in: PubMed
  13. Han T, Marasco WA. Structural basis of influenza virus neutralization. Ann N Y Acad Sci. 2011 Jan; 1217:178-90.
    View in: PubMed
  14. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011 Jan 17; 208(1):181-93.
    View in: PubMed
  15. Hashem AM, Van Domselaar G, Li C, Wang J, She YM, Cyr TD, Sui J, He R, Marasco WA, Li X. Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochem Biophys Res Commun. 2010 Dec 10; 403(2):247-51.
    View in: PubMed
  16. Herschhorn A, Marasco WA, Hizi A. Antibodies and lentiviruses that specifically recognize a T cell epitope derived from HIV-1 Nef protein and presented by HLA-C. J Immunol. 2010 Dec 15; 185(12):7623-32.
    View in: PubMed
  17. Kuan CT, Srivastava N, McLendon RE, Marasco WA, Zalutsky MR, Bigner DD. Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. Int J Cancer. 2010 Aug 1; 127(3):598-611.
    View in: PubMed
  18. Xu C, Lo A, Yammanuru A, Tallarico AS, Brady K, Murakami A, Barteneva N, Zhu Q, Marasco WA. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS One. 2010; 5(3):e9625.
    View in: PubMed
  19. Centeno CJ, Schultz JR, Cheever M, Robinson B, Freeman M, Marasco W. Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther. 2010 Mar; 5(1):81-93.
    View in: PubMed
  20. Sultana H, Foellmer HG, Neelakanta G, Oliphant T, Engle M, Ledizet M, Krishnan MN, Bonafé N, Anthony KG, Marasco WA, Kaplan P, Montgomery RR, Diamond MS, Koski RA, Fikrig E. Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody. J Immunol. 2009 Jul 1; 183(1):650-60.
    View in: PubMed
  21. Gennari F, Lopes L, Verhoeyen E, Marasco W, Collins MK. Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells. Hum Gene Ther. 2009 Jun; 20(6):554-62.
    View in: PubMed
  22. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009 Mar; 16(3):265-73.
    View in: PubMed
  23. Nakase K, Cheng J, Zhu Q, Marasco WA. Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells. J Leukoc Biol. 2009 Jan; 85(1):165-74.
    View in: PubMed
  24. Sui J, Aird DR, Tamin A, Murakami A, Yan M, Yammanuru A, Jing H, Kan B, Liu X, Zhu Q, Yuan QA, Adams GP, Bellini WJ, Xu J, Anderson LJ, Marasco WA. Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog. 2008 Nov; 4(11):e1000197.
    View in: PubMed
  25. Taube R, Zhu Q, Xu C, Diaz-Griffero F, Sui J, Kamau E, Dwyer M, Aird D, Marasco WA. Lentivirus display: stable expression of human antibodies on the surface of human cells and virus particles. PLoS One. 2008; 3(9):e3181.
    View in: PubMed
  26. Huang IC, Li W, Sui J, Marasco W, Choe H, Farzan M. Influenza A virus neuraminidase limits viral superinfection. J Virol. 2008 May; 82(10):4834-43.
    View in: PubMed
  27. Lo AS, Zhu Q, Marasco WA. Intracellular antibodies (intrabodies) and their therapeutic potential. Handb Exp Pharmacol. 2008; (181):343-73.
    View in: PubMed
  28. Rodgerson D, Rothenberg R and Marasco WA. . The Collection, Processing and Storage of Adult Stem Cells – A Bio-Insurance Policy for Personalized Medical Therapies. Life Extension Foundation magazine. 2008.
  29. Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol. 2007 Dec; 25(12):1421-34.
    View in: PubMed
  30. Xu C, Sui J, Tao H, Zhu Q, Marasco WA. Human anti-CXCR4 antibodies undergo VH replacement, exhibit functional V-region sulfation, and define CXCR4 antigenic heterogeneity. J Immunol. 2007 Aug 15; 179(4):2408-18.
    View in: PubMed
  31. Li W, Sui J, Huang IC, Kuhn JH, Radoshitzky SR, Marasco WA, Choe H, Farzan M. The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. Virology. 2007 Oct 25; 367(2):367-74.
    View in: PubMed
  32. Cheng J, Kydd AR, Nakase K, Noonan KM, Murakami A, Tao H, Dwyer M, Xu C, Zhu Q, Marasco WA. Negative regulation of the SH2-homology containing protein-tyrosine phosphatase-1 (SHP-1) P2 promoter by the HTLV-1 Tax oncoprotein. Blood. 2007 Sep 15; 110(6):2110-20.
    View in: PubMed
  33. Lo A, Zhu QK and Marasco WA. . Intracellular antibodies (Intrabodies) as specific molecules for therapeutic applications. In Handbook of Experimental Pharmacology. Chernajovsky Y, ed. 2007.
  34. Hwang WC, Lin Y, Santelli E, Sui J, Jaroszewski L, Stec B, Farzan M, Marasco WA, Liddington RC. Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem. 2006 Nov 10; 281(45):34610-6.
    View in: PubMed
  35. Kanai R, Kar K, Anthony K, Gould LH, Ledizet M, Fikrig E, Marasco WA, Koski RA, Modis Y. Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. J Virol. 2006 Nov; 80(22):11000-8.
    View in: PubMed
  36. Bai J, Demirjian A, Sui J, Marasco W, Callery MP. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun. 2006 Oct 6; 348(4):1245-53.
    View in: PubMed
  37. Yuan QA, Simmons HH, Robinson MK, Russeva M, Marasco WA, Adams GP. Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Mol Cancer Ther. 2006 Aug; 5(8):2096-105.
    View in: PubMed
  38. Marasco WA*, Sui J. . Convergent Combination Immunotherapy for the Prevention and Treatment of SARS. The 5th International Congress on Recombinant Antibodies. Zurich, Switzerland. 2006.
  39. Si Z, Vandegraaff N, O'huigin C, Song B, Yuan W, Xu C, Perron M, Li X, Marasco WA, Engelman A, Dean M, Sodroski J. Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. Proc Natl Acad Sci U S A. 2006 May 9; 103(19):7454-9.
    View in: PubMed
  40. Marasco WA*, Sui J. . Passive immunotherapy in an outbreak setting. A case of SARS. From Concept to Clinic. Cambridge Health Institute’s 7th Annual Meeting, Boston, MA. 2006.
  41. Tarnovitski N, Matthews LJ, Sui J, Gershoni JM, Marasco WA. Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides. J Mol Biol. 2006 May 26; 359(1):190-201.
    View in: PubMed
  42. Sui J and Marasco WA. . Immunopathogenesis and Immunotherapy of SARS. In Challenges of Severe Acute Respiratory Syndrome. Chan JCK and Wong VCW, eds. 2006.
  43. Sui J, Aird DR, Marasco WA*. . Human neutralizing antibodies for convergent immunotherapy against SARS. 16th Annual International Conference on Antibody Engineering, San Diego, CA. 2005.
  44. Gould LH, Sui J, Foellmer H, Oliphant T, Wang T, Ledizet M, Murakami A, Noonan K, Lambeth C, Kar K, Anderson JF, de Silva AM, Diamond MS, Koski RA, Marasco WA, Fikrig E. Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol. 2005 Dec; 79(23):14606-13.
    View in: PubMed
  45. Marasco WA*. . A strategy to move potent neutralizing anti-SARS monoclonal antibodies into clinical trials in an outbreak setting. The Second China International Symposium on Antibody Engineering. Invited Speaker. Therapeutic Antibodies for Non-Malignant Diseases. Beijing, China,. 2005.
  46. Marasco WA*, Sui J. . A Strategy Toward Convergent Combination Immunotherapy for SARS. ICLAS-CALAS International Symposium. Animal Models of Infectious Diseases. Beijing, China. 2005.
  47. Lo AS-Y, Dwyer MR, Appleman LJ, Marasco WA*. . Development of Renal Cell Carcinoma (RCC) Vaccine against G250 by Co-Expression of G250 Extracellular Domain-Fc Fusion Protein and IL-2 Using 2A Self-Processing Peptide. CHI Conference. Cancer Immunotheerptics and Targeted Cancer Therapies, Boston, MA. 2005.
  48. Marasco, WA*, Cheng J, and Noonan K. . Role of HTLV-1 Tax in SH2-containing Tyrosine Phosphatase-1 (SHP-1) Promoter Silencing in Acute Infection and Adult T-Cell Leukemia. 12th International Conference on Human Retrovirology: HTLV-1 and Related Viruses. Montego Bay, Jamaica. 2005.
  49. Cheng J, Noonan K and Marasco WA*. . Suppresses Shp-1 (SH2-containing Tyrosine Phosphatase-1) Gene Expression and Facilitates Leukemogenesis Through Tax-Promoter Interaction. 12th International Conference on Human Retrovirology: HTLV-1 and Related Viruses. Montego Bay, Jamaica. 2005.
  50. Bal HP, Cheng J, Murakami A, Tallarico AS, Wang W, Zhou D, Vasicek TJ, Marasco WA. GITR overexpression on CD4+CD25+ HTLV-1 transformed cells: detection by massively parallel signature sequencing. Biochem Biophys Res Commun. 2005 Jul 1; 332(2):569-84.
    View in: PubMed
  51. Qin C, Wang J, Wei Q, She M, Marasco WA, Jiang H, Tu X, Zhu H, Ren L, Gao H, Guo L, Huang L, Yang R, Cong Z, Guo L, Wang Y, Liu Y, Sun Y, Duan S, Qu J, Chen L, Tong W, Ruan L, Liu P, Zhang H, Zhang J, Zhang H, Liu D, Liu Q, Hong T, He W. An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus. J Pathol. 2005 Jul; 206(3):251-9.
    View in: PubMed
  52. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, Marasco WA, Lieberman J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005 Jun; 23(6):709-17.
    View in: PubMed
  53. Marasco WA. Therapeutic antibody gene transfer. Nat Biotechnol. 2005 May; 23(5):551-2.
    View in: PubMed
  54. Sui J, Li W, Roberts A, Matthews LJ, Murakami A, Vogel L, Wong SK, Subbarao K, Farzan M, Marasco WA. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol. 2005 May; 79(10):5900-6.
    View in: PubMed
  55. Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K, Vasilieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, Farzan M. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005 Apr 20; 24(8):1634-43.
    View in: PubMed
  56. Bai J, Sui J, Demirjian A, Vollmer CM, Marasco W, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res. 2005 Mar 15; 65(6):2344-52.
    View in: PubMed
  57. Cheng J, Kydd A, Noonan K, Xu C, Murakami A, and Marasco WA*. . Role of SHP-1 deregulation in HTLV-1 leukemogenesis. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA. 2005.
  58. Marasco, WA*, Sui J, Xu C, Murakami A and Noonan K. . Potential Use of Human Monoclonal Antibodies Against CXCR4 for the Prevention and Treatment of Breast Cancer Metastasis. Keystone Symposium on Antibody Based Therapeutics for Cancer, Santa Fe, NM. 2005.
  59. Masiero S, Del Vecchio C, Gavioli R, Mattiuzzo G, Cusi MG, Micheli L, Gennari F, Siccardi A, Marasco WA, Palù G, Parolin C. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther. 2005 Feb; 12(4):299-310.
    View in: PubMed
  60. Marasco WA*. . A strategy for Global Collaborations to Develop Human Monoclonal Antibody (mAb) Drugs for the Treatment of Cancer. Oncology Research. 2005; 15:458.
  61. Gould LH, Sui J, Ledizet M, Foellmer H, Koski R, Marasco WA*, and Fikrig E. . Preventive and therapeutic immunization against lethal murine West Nile virus infection with a bivalent human single-chain antibody (scFv)-Fc fusion protein and rabbit polyclonal antibody against the envelope protein. American Association of Tropical Medicine and Hygiene Annual Meeting, Miami Beach, FL. 2004.
  62. Gennari F, Lopes L, Marasco WA* and Collins MK. . Targeting Dendritic Cells: Selection of Single Chain Antibodies from a Human Phage Display Library. The 12th Annual Congress of the European Society of Gene Therapy, Tampere, Finland. 2004.
  63. Busch A, Marasco WA, Doebis C, Volk HD, Seifert M. MHC class I manipulation on cell surfaces by gene transfer of anti-MHC class I intrabodies--a tool for decreased immunogenicity of allogeneic tissue and cell transplants. Methods. 2004 Oct; 34(2):240-9.
    View in: PubMed
  64. Sui J, Xu C, Murakami A, Noonan K and Marasco WA*. . Isolation of human antibodies against CXCR4 by paramagnetic proteoliposomes for prevention and treatment of breast cancer metastases. The Susan G, Komen Cancer Foundation Pathways to a Promise. New York, NY. 2004.
  65. Bal HP, Cheng J, Murakami A, Wang W, Vasicek TJ, and Marasco WA*. . Transcriptional deregulation in adult T-cell leukemia: Genome-wide transcriptional profiling of acutely HTLV-1 transformed cells using Massively Parallel Signature Sequencing. 95th AACR Annual Meeting, Orlando, FL. 2004.
  66. Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallarico AS, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M, Marasco WA. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A. 2004 Feb 24; 101(8):2536-41.
    View in: PubMed
  67. Cheng JD, Valianou M, Simmons H, Jann P, Yuan QA, Russeva MG, Marasco WA*, Cukierman E, Adams GP, and Weiner LM. Abrogation of Fibroblast Activation Protein Enzymatic Activity Attenuates Tumor Growth. AACR Annual Meeting, Dana Point, CA. 2004.
  68. Cheng J, Kydd A, Noonan K, Xu C, Murakami A, and Marasco WA*. . Role of SHP-1 deregulation in HTLV-1 leukemogenesis. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA. 2004.
  69. Gennari F, Mehta S, Wang Y, St Clair Tallarico A, Palu G, Marasco WA. Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-kappaB transactivation. J Mol Biol. 2004 Jan 2; 335(1):193-207.
    View in: PubMed
  70. Cheng J, Zhang D, Zhou C, Marasco WA. Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells. Leuk Res. 2004 Jan; 28(1):71-82.
    View in: PubMed
  71. Sui J, Bai J, St Clair Tallarico A, Xu C, Marasco WA. Identification of CD4 and transferrin receptor antibodies by CXCR4 antibody-guided Pathfinder selection. Eur J Biochem. 2003 Nov; 270(22):4497-506.
    View in: PubMed
  72. Vyas J and Marasco WA*. . Fatal Fulminant Hepatic Failure from Adenovirus in Allogeneic Bone Marrow Transplant Patients. 41st Annual Meeting of Infectious Diseases Society of America. 2003.
  73. Marty FM, Cosimi L, Marasco WA*, Rubin RH and Baden LR. . Breakthrough Zygomycosis in Allogeneic Hematopoietic Stem Cell Transplant Recipients Who Received Voriconazole as Prophylaxis or Empiric Therapy. 43rd ICAAC. 2003.
  74. Xu C, Kontos H, Tallarico A, Murakami A, Morse LJ, Cheng J and Marasco WA*. . Generation and Characterization of Engineered Human Anti-CCR5 Antibodies. 3rd Annual Harvard Medical School Centers for AIDS Research Symposium, Boston, MA. 2003.
  75. Cheng J, Zhang D, Zhou C and Marasco WA*. . Down-Regulation of SHP1 and Up-Regulation of Negative Regulators of JAK/STAT Signaling in HTLV-1 Transformed Cell Lines and Freshly Transformed Human Peripheral Blood CD4+ T-cells. 3rd Annual Harvard Medical School Centers for AIDS Research Symposium, Boston, MA. 2003.
  76. Zhang D, Murakami A, Johnson RP, Sui J, Cheng J, Bai J, Marasco WA. Optimization of ex vivo activation and expansion of macaque primary CD4-enriched peripheral blood mononuclear cells for use in anti-HIV immunotherapy and gene therapy strategies. J Acquir Immune Defic Syndr. 2003 Mar 1; 32(3):245-54.
    View in: PubMed
  77. Marasco WA*, Murakami A, Gennari F. . Intrabodies as Tools to Perturb Cellular Function. Guest Speaker for the Antibody-Based Therapeutics for Cancer, 2003 Keystone Symposia. 2003.
  78. Zhu Q and Marasco WA. . Intracellular targeting of antibodies in mammalian cells. In New Comprehensive Biocehmistry : Gene Transfer and Expression in Mammalian Cells. Savvas C. Makrides , ed. 2003; 573 – 623.
  79. Sui J, Marasco WA. Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor. Virology. 2002 Nov 10; 303(1):9-14.
    View in: PubMed
  80. Bai J, Sui J, Zhu RY, Tallarico AS, Gennari F, Zhang D, Marasco WA. Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J Biol Chem. 2003 Jan 17; 278(3):1433-42.
    View in: PubMed
  81. Mhashilkar AM, Doebis C, Seifert M, Busch A, Zani C, Soo Hoo J, Nagy M, Ritter T, Volk HD, Marasco WA. Intrabody-mediated phenotypic knockout of major histocompatibility complex class I expression in human and monkey cell lines and in primary human keratinocytes. Gene Ther. 2002 Mar; 9(5):307-19.
    View in: PubMed
  82. Li X, Josef J, Marasco WA. Hiv-1 Tat can substantially enhance the capacity of NIK to induce IkappaB degradation. Biochem Biophys Res Commun. 2001 Aug 24; 286(3):587-94.
    View in: PubMed
  83. Ogueta SB, Yao F, Marasco WA. Design and in vitro characterization of a single regulatory module for efficient control of gene expression in both plasmid DNA and a self-inactivating lentiviral vector. Mol Med. 2001 Aug; 7(8):569-79.
    View in: PubMed
  84. Li X, Stuckert P, Bosch I, Marks JD, Marasco WA. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Cancer Gene Ther. 2001 Aug; 8(8):555-65.
    View in: PubMed
  85. Marasco WA. Intrabodies as antiviral agents. Curr Top Microbiol Immunol. 2001; 260:247-70.
    View in: PubMed
  86. Marasco WA. . Intrabodies as anti-viral agents. In Current Topics in Microbiology and Immunology. Dennis R. Burton,ed. 2001; 260:247-70.
  87. Marasco, WA. Expression vectors and methods of use. 2000.
  88. Li X, Multon MC, Henin Y, Schweighoffer F, Venot C, Josef J, Zhou C, LaVecchio J, Stuckert P, Raab M, Mhashilkar A, Tocque B, Marasco WA. Grb3-3 is up-regulated in HIV-1-infected T-cells and can potentiate cell activation through NFATc. J Biol Chem. 2000 Oct 6; 275(40):30925-33.
    View in: PubMed
  89. Li X, Multon MC, Henin Y, Schweighoffer F, Venot C, LaVecchio J, Josef J, Stuckert P, Mhashilkar A, Tocqué B, Marasco WA. Upregulation of the apoptosis-associated protein Grb3-3 in HIV-1-infected human CD4(+) lymphocytes. Biochem Biophys Res Commun. 2000 Sep 16; 276(1):362-70.
    View in: PubMed
  90. Marasco, WA. Method of intracellular binding of target molecules. 2000.
  91. Mirzabekov T, Kontos H, Farzan M, Marasco W, Sodroski J. Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5. Nat Biotechnol. 2000 Jun; 18(6):649-54.
    View in: PubMed
  92. Song SU and Marasco WA. . Rapid establishment of myeloma cell lines expressing Fab (Tac)-Protamine, A targetable protein vector, directed against the high affinity alpha chain of the human interleukin-2 receptor. In Methods in Molecular Biology. Eric Kmiec, ed. 2000; 133:156-66.
  93. Song SU, Marasco WA. Rapid establishment of myeloma cell lines expressing Fab(Tac)-protamine, a targetable protein vector, directed against high-affinity alpha-chain of human interleukin-2 receptor. Methods Mol Biol. 2000; 133:157-66.
    View in: PubMed
  94. Marasco, WA. Intracellular targeting of endogenous proteins. 1999.
  95. Marasco WA, LaVecchio J, Winkler A. Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J Immunol Methods. 1999 Dec 10; 231(1-2):223-38.
    View in: PubMed
  96. Zhu Q, Zeng C, Huhalov A, Yao J, Turi TG, Danley D, Hynes T, Cong Y, DiMattia D, Kennedy S, Daumy G, Schaeffer E, Marasco WA, Huston JS. Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7. J Immunol Methods. 1999 Dec 10; 231(1-2):207-22.
    View in: PubMed
  97. Poznansky MC, La Vecchio J, Silva-Arietta S, Porter-Brooks J, Brody K, Olszak IT, Adams GB, Ramstedt U, Marasco WA, Scadden DT. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat. Hum Gene Ther. 1999 Oct 10; 10(15):2505-14.
    View in: PubMed
  98. Mhashilkar AM, LaVecchio J, Eberhardt B, Porter-Brooks J, Boisot S, Dove JH, Pumphrey C, Li X, Weissmahr RN, Ring DB, Ramstedt U, Marasco WA. Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies. Hum Gene Ther. 1999 Jun 10; 10(9):1453-67.
    View in: PubMed
  99. Marasco, WA. Reactive neutralizing human anti-gp120 recombinant antibody, DNA coding the same and use thereof. 1998.
  100. Marasco, WA. Method of intracellular binding of target molecules. 1998.
  101. Marasco, WA. Method of intracellular binding of target molecules. 1998.
  102. Marasco WA, Chen S, Richardson JH, Ramstedt U, Jones SD. Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. Hum Gene Ther. 1998 Jul 20; 9(11):1627-42.
    View in: PubMed
  103. Richardson JH, Hofmann W, Sodroski JG, Marasco WA. Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector. Gene Ther. 1998 May; 5(5):635-44.
    View in: PubMed
  104. Poznansky MC, Foxall R, Mhashilkar A, Coker R, Jones S, Ramstedt U, Marasco W. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat. Hum Gene Ther. 1998 Mar 1; 9(4):487-96.
    View in: PubMed
  105. Pumphrey CY, Marasco WA. The therapeutic potential of intracellular antibodies. BioDrugs. 1998 Mar; 9(3):179-85.
    View in: PubMed
  106. Vallat AV, De Girolami U, He J, Mhashilkar A, Marasco W, Shi B, Gray F, Bell J, Keohane C, Smith TW, Gabuzda D. Localization of HIV-1 co-receptors CCR5 and CXCR4 in the brain of children with AIDS. Am J Pathol. 1998 Jan; 152(1):167-78.
    View in: PubMed
  107. Jones SD and Marasco WA. . Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression. In Advanced Drug Reviews. 1998; 31:153-170.
  108. Marasco WA. Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression. Adv Drug Deliv Rev. 1998 Apr 6; 31(1-2):153-170.
    View in: PubMed
  109. Richardson JH, Waldmann TA, Sodroski JG, Marasco WA. Inducible knockout of the interleukin-2 receptor alpha chain: expression of the high-affinity IL-2 receptor is not required for the in vitro growth of HTLV-I-transformed cell lines. Virology. 1997 Oct 27; 237(2):209-16.
    View in: PubMed
  110. Mhashilkar AM, Biswas DK, LaVecchio J, Pardee AB, Marasco WA. Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists. J Virol. 1997 Sep; 71(9):6486-94.
    View in: PubMed
  111. Levin R, Mhashilkar AM, Dorfman T, Bukovsky A, Zani C, Bagley J, Hinkula J, Niedrig M, Albert J, Wahren B, Göttlinger HG, Marasco WA. Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17. Mol Med. 1997 Feb; 3(2):96-110.
    View in: PubMed
  112. Marasco WA. Intrabodies: turning the humoral immune system outside in for intracellular immunization. Gene Ther. 1997 Jan; 4(1):11-5.
    View in: PubMed
  113. Richardson JH and Marasco WA. . Studies on the phenotypic ¡§knockout¡¨ of the human interleukin-2 receptor ƒÑ chain. In Intrabodies: Basic Research and Clinical Gene Therapy Applications. Molecular Biology Intelligence Unit. Marasco WA, ed. 1997.
  114. Rondon IJ and Marasco WA. . Gene therapy for HIV-1 using intracellular antibodies against HIV-1 Gag proteins. In Intrabodies: Basic Research and Clinical Gene Therapy Applications. Molecular Biology Intelligence Unit. Marasco WA, ed. 1997.
  115. Marasco WA. . Intrabodies: From antibody genes to intracellular immunization. In The Antibodies, Zanetti M and Capra JD, eds. 1997; 4.
  116. Marasco WA. . Designing Intrabodies: Structural features and the use of intracellular trafficking signals. In Intrabodies: Basic Research and Clinical Gene Therapy Applications. Molecular Biology Intelligence Unit. Marasco WA, ed. 1997.
  117. Pumphrey CY and Marasco WA. . The therapeutic potential of intracellular antibodies. In BioDrugs. Beedle AS, ed. 1997.
  118. Jones SD and Marasco WA. . Intracellular antibodies (intrabodies): Potential applications in transgenic animal research and engineered resistance to pathogens. In Transgenic Animals - Generation and Use. Houdebine L-M, ed. . 1997; 74:501-6.
  119. Rondon IJ, Marasco WA. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. Annu Rev Microbiol. 1997; 51:257-83.
    View in: PubMed
  120. Mhashilkar AM and Marasco WA. . Intrabodies targeted against regulatory epitopes of HIV-1: Tat and Rev as two significant targets for gene therapy. In Intrabodies: Basic Research and Clinical Gene Therapy Applications. Molecular Biology Intelligence Unit. Marasco WA, ed. 1997.
  121. Chen JD, Yang Q, Yang AG, Marasco WA, Chen SY. Intra- and extracellular immunization against HIV-1 infection with lymphocytes transduced with an AAV vector expressing a human anti-gp120 antibody. Hum Gene Ther. 1996 Aug 20; 7(13):1515-25.
    View in: PubMed
  122. Chen SY, Marasco WA. Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Semin Oncol. 1996 Feb; 23(1):148-53.
    View in: PubMed
  123. Marasco WA. . Gene Therapy and Research Applications of Intrabodies for Human Infectious Diseases. In The Use of Ectopic Antibody Expression for Intracellular and Extracellular Immunization. Biocca S. And Cattaneo A., eds. 1996.
  124. Mhashilkar AM, Agarwal S, Levin R, and Marasco WA. . Looking ahead: Combination of intracellular single-chain antibodies and other genetic-based anti-HIV-1 approaches hold promise as an effective strategy for AIDS gene therapy. In Drugs, News and Perspectives. 1996; 9:220-7.
  125. Mhashilkar AM and Marasco WA. . Intrabody-based gene therapy approaches against HIV-1. In -Advancing a New Agenda for AIDS Research, Poznansky M.C., Coker R.J. and Gilles P., eds. 1996.
  126. Richardson JH, Marasco WA. Intracellular antibodies: development and therapeutic potential. Trends Biotechnol. 1995 Aug; 13(8):306-10.
    View in: PubMed
  127. Marasco WA. Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy. Immunotechnology. 1995 May; 1(1):1-19.
    View in: PubMed
  128. Richardson JH, Sodroski JG, Waldmann TA, Marasco WA. Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. Proc Natl Acad Sci U S A. 1995 Apr 11; 92(8):3137-41.
    View in: PubMed
  129. Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Helland DG, Marasco WA. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J. 1995 Apr 3; 14(7):1542-51.
    View in: PubMed
  130. Chen SY, Zani C, Khouri Y, Marasco WA. Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Ther. 1995 Mar; 2(2):116-23.
    View in: PubMed
  131. Khouri YF, McIntosh K, Cavacini L, Posner M, Pagano M, Tuomala R, Marasco WA. Vertical Transmission of HIV-1. Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodies. J Clin Invest. 1995 Feb; 95(2):732-7.
    View in: PubMed
  132. Becker EL and Marasco WA.* . Chemotaxis and activation of neutrophils. In Symposium on Chemical Mediators of Inflammation. Japan, Cohen S, Hayashi H, Saito K, and Takada A. eds. 1995; 220-4.
  133. Chen S-Y, Mhashilkar AM, and Marasco WA. . Intracellular antibodies for HIV-1 gene therapy. In Expert Opinion on Investigational Drugs. 1995; 4:823-31.
  134. Smith C, Marasco WA, and Böhnlein B. . Gene therapy. In HIV: A Practical Approach: Volume 2, Biochemistry, Molecular Biology, Drug Discovery. Karn J, ed. 1995.
  135. Bagley J, Dillon PJ, Rosen C, Robinson J, Sodroski J, Marasco WA. Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120. Mol Immunol. 1994 Oct; 31(15):1149-60.
    View in: PubMed
  136. Chen SY, Khouri Y, Bagley J, Marasco WA. Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc Natl Acad Sci U S A. 1994 Jun 21; 91(13):5932-6.
    View in: PubMed
  137. Chen SY, Bagley J, Marasco WA. Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum Gene Ther. 1994 May; 5(5):595-601.
    View in: PubMed
  138. Marasco WA, Szilvay AM, Kalland KH, Helland DG, Reyes HM, Walter RJ. Spatial association of HIV-1 tat protein and the nucleolar transport protein B23 in stably transfected Jurkat T-cells. Arch Virol. 1994; 139(1-2):133-54.
    View in: PubMed
  139. Marasco WA, Haseltine WA, Chen SY. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci U S A. 1993 Aug 15; 90(16):7889-93.
    View in: PubMed
  140. Marasco WA, Bagley J, Zani C, Posner M, Cavacini L, Haseltine WA, Sodroski J. Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody. J Clin Invest. 1992 Oct; 90(4):1467-78.
    View in: PubMed
  141. Garcia LW, Hemphill RB, Marasco WA, Ciano PS. Acquired immunodeficiency syndrome with disseminated toxoplasmosis presenting as an acute pulmonary and gastrointestinal illness. Arch Pathol Lab Med. 1991 May; 115(5):459-63.
    View in: PubMed
  142. Bradley SF, Gordon JJ, Baumgartner DD, Marasco WA, Kauffman CA. Group C streptococcal bacteremia: analysis of 88 cases. Rev Infect Dis. 1991 Mar-Apr; 13(2):270-80.
    View in: PubMed
  143. Sannomiya P, Craig RA, Clewell DB, Suzuki A, Fujino M, Till GO, Marasco WA. Characterization of a class of nonformylated Enterococcus faecalis-derived neutrophil chemotactic peptides: the sex pheromones. Proc Natl Acad Sci U S A. 1990 Jan; 87(1):66-70.
    View in: PubMed
  144. Marasco WA, Lester S, Parsonnet J. Unusual presentation of cat scratch disease in a patient positive for antibody to the human immunodeficiency virus. Rev Infect Dis. 1989 Sep-Oct; 11(5):793-803.
    View in: PubMed
  145. Janeczek AH, Marasco WA, van Alten PJ, Walter RJ. Autoradiographic analysis of formylpeptide chemoattractant binding, uptake and intracellular processing by neutrophils. J Cell Sci. 1989 Sep; 94 ( Pt 1):155-68.
    View in: PubMed
  146. Feltner DE, Marasco WA. Regulation of formyl peptide receptor binding to rabbit neutrophil plasma membranes. Use of monovalent cations, guanine nucleotides, and bacterial toxins to discriminate among different states of the receptor. J Immunol. 1989 Jun 1; 142(11):3963-70.
    View in: PubMed
  147. Atkinson YH, Lopez AF, Marasco WA, Lucas CM, Wong GG, Burns GF, Vadas MA. Recombinant human granulocyte-macrophage colony-stimulating factor (rH GM-CSF) regulates f Met-Leu-Phe receptors on human neutrophils. Immunology. 1988 Jul; 64(3):519-25.
    View in: PubMed
  148. Atkinson YH, Marasco WA, Lopez AF, Vadas MA. Recombinant human tumor necrosis factor-alpha. Regulation of N-formylmethionylleucylphenylalanine receptor affinity and function on human neutrophils. J Clin Invest. 1988 Mar; 81(3):759-65.
    View in: PubMed
  149. Marasco WA and Ward PA. . Chemotactic factors of bacterial origin. Chapter 19. In Immunological Techniques. Part L. Chemotaxis and Inflammation. Methods in Enzymology. DiSabato G, Langone JJ, and VanVunakis H, eds. 1988; Vol. 162:198-214.
  150. Marasco WA, Ward PA. Chemotactic factors of bacterial origin. Methods Enzymol. 1988; 162:198-214.
    View in: PubMed
  151. Marasco WA, Gikas PW, Azziz-Baumgartner R, Hyzy R, Eldredge CJ, Stross J. Ibuprofen-associated renal dysfunction. Pathophysiologic mechanisms of acute renal failure, hyperkalemia, tubular necrosis, and proteinuria. Arch Intern Med. 1987 Dec; 147(12):2107-16.
    View in: PubMed
  152. Walter RJ, Marasco WA. Direct visualization of formylpeptide receptor binding on rounded and polarized human neutrophils: cellular and receptor heterogeneity. J Leukoc Biol. 1987 May; 41(5):377-91.
    View in: PubMed
  153. Walter RJ and Marasco WA. . Heterogeneity and topographical asymmetry of formyl peptide receptor binding on polymorphonuclear leukocytes. In The Biology of Phagocytes in Health and Disease. Mauri C, Rizzo SC, and Ricevuti G, eds. 1987; 9-21.
  154. Feltner DE, Smith RH, Marasco WA. Characterization of the plasma membrane bound GTPase from rabbit neutrophils. I. Evidence for an Ni-like protein coupled to the formyl peptide, C5a, and leukotriene B4 chemotaxis receptors. J Immunol. 1986 Sep 15; 137(6):1961-70.
    View in: PubMed
  155. Duque RE, Fantone JC, Kramer C, Marasco WA, Phan SH. Inhibition of neutrophil activation by p-bromophenacyl bromide and its effects on phospholipase A2. Br J Pharmacol. 1986 Jun; 88(2):463-72.
    View in: PubMed
  156. Marasco WA, Becker KM, Feltner DE, Brown CS, Ward PA, Nairn R. Covalent affinity labeling, detergent solubilization, and fluid-phase characterization of the rabbit neutrophil formyl peptide chemotaxis receptor. Biochemistry. 1985 Apr 23; 24(9):2227-36.
    View in: PubMed
  157. Marasco WA, Ward PA, Feltner DE, Varani J. Chemotactic factor binding by metastatic tumour cells: evidence for a formyl-peptide receptor on a non-myelogenous cell. J Cell Sci. 1985 Feb; 73:121-34.
    View in: PubMed
  158. Marasco WA, Feltner DE, Ward PA. Formyl peptide chemotaxis receptors on the rat neutrophil: experimental evidence for negative cooperativity. J Cell Biochem. 1985; 27(4):359-75.
    View in: PubMed
  159. Nairn R, Smith RH, Brown CS, Marasco WA. What are the molecular characteristics of the neutrophil receptor for chemotactic formylated peptides? Surv Immunol Res. 1985; 4(3):213-9.
    View in: PubMed
  160. Marasco WA, Charles J, and Ward PA. . A search for "Internal Image" anti-idiotypic antibodies: A subpopulation of anti-f Met-Leu-Phe anti-idiotypic antibodies binds to the formyl peptide chemotaxis receptor of the neutrophil and to several genetically unrelated anti-f Met-Leu-Phe antibodies. In UCLA Symposium on Molecular and Cellular Biology. New Series, Reisfeld RA and Sell S. eds. 1985; 27:327-44.
  161. Walter RJ, Marasco WA. Localization of chemotactic peptide receptors on rabbit neutrophils. Exp Cell Res. 1984 Oct; 154(2):613-8.
    View in: PubMed
  162. Marasco WA, Phan SH, Krutzsch H, Showell HJ, Feltner DE, Nairn R, Becker EL, Ward PA. Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J Biol Chem. 1984 May 10; 259(9):5430-9.
    View in: PubMed
  163. Fantone JC, Marasco WA, Elgas LJ, Ward PA. Stimulus specificity of prostaglandin inhibition of rabbit polymorphonuclear leukocyte lysosomal enzyme release and superoxide anion production. Am J Pathol. 1984 Apr; 115(1):9-16.
    View in: PubMed
  164. Kunkel SL, Manderino GL, Marasco W, Kaercher K, Hirata AA, Ward PA. A specific enzyme-linked immunosorbent assay (ELISA) for the determination of human C5a antigen. J Immunol Methods. 1983 Sep 16; 62(3):305-14.
    View in: PubMed
  165. Marasco WA, Fantone JC, Freer RJ, Ward PA. Characterization of the rat neutrophil formyl peptide chemotaxis receptor. Am J Pathol. 1983 Jun; 111(3):273-81.
    View in: PubMed
  166. Fantone JC, Marasco WA, Elgas LJ, Ward PA. Anti-inflammatory effects of prostaglandin E1: in vivo modulation of the formyl peptide chemotactic receptor on the rat neutrophil. J Immunol. 1983 Apr; 130(4):1495-7.
    View in: PubMed
  167. Marasco WA, Fantone JC, Ward PA. Spasmogenic activity of chemotactic N-formylated oligopeptides: identity of structure--function relationships for chemotactic and spasmogenic activities. Proc Natl Acad Sci U S A. 1982 Dec; 79(23):7470-3.
    View in: PubMed
  168. Marasco WA, Becker EL. Anti-idiotype as antibody against the formyl peptide chemotaxis receptor of the neutrophil. J Immunol. 1982 Feb; 128(2):963-8.
    View in: PubMed
  169. Marasco WA, Showell HJ, Freer RJ, Becker EL. Anti-f Met-Leu-Phe: similarities in fine specificity with the formyl peptide chemotaxis receptor of the neutrophil. J Immunol. 1982 Feb; 128(2):956-62.
    View in: PubMed
  170. Marasco WA, Showell HJ, Becker EL. Substance P binds to the formylpeptide chemotaxis receptor on the rabbit neutrophil. Biochem Biophys Res Commun. 1981 Apr 30; 99(4):1065-72.
    View in: PubMed
  171. Marasco WA, Becker EL, Oliver JM. The ionic basis of chemotaxis. Separate cation requirements for neutrophil orientation and locomotion in a gradient of chemotactic peptide. Am J Pathol. 1980 Mar; 98(3):749-68.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Marasco's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_